unknown
Stage
1
Investors
About
Braeburn Pharmaceuticals develops and commercializes treatments for opioid use disorder; its lead product BRIXADI is a buprenorphine extended‑release subcutaneous injection approved by the FDA for the treatment of moderate to severe opioid use disorder.
Explore Braeburn's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.